CRISPR Therapeutics AG – Value Analysis (NASDAQ:CRSP) : October 30, 2017

Capitalcube gives CRISPR Therapeutics AG a score of 55.

Our analysis is based on comparing CRISPR Therapeutics AG with the following peers – Plandai Biotechnology, Inc., Pieris Pharmaceuticals, Inc., PDL BioPharma, Inc. and Bioblast Pharma Ltd. (PLPL-US, PIRS-US, PDLI-US and ORPN-US).

Investment Outlook

CRISPR Therapeutics AG has a fundamental score of 55 and has a relative valuation of OVERVALUED.

Fundamental Score

Access our research and ratings on CRISPR Therapeutics AG

Company Overview

  • Considering peers, relative outperformance over the last year and the last month suggest a leading position.
  • It currently trades at a Price/Book ratio of (3.89).
  • CRSP-US‘s earnings and EBITDA are both negative which suggest that P/E or Price/EBITDA are not meaningful to make this analysis between operating advantage (ROE) and growth expectations (as suggested by P/E or P/EBITDA).
  • CRSP-US employs relatively high amounts of assets while generating relatively median profit margins.
  • The company’s year-on-year change in revenues and earnings are better than the median among its peer group.
  • Over the last five years, CRSP-US‘s return on assets has improved from below median to better than the median among its peers, suggesting that the company has improved its relative operations markedly.
  • CRSP-US currently does not have any debt.

Access our research and ratings on CRISPR Therapeutics AG

Leverage & Liquidity

CRSP-US currently does not have any debt.

  • We consider the company to have a Quick & Able profile as it currently does not have any debt. In comparison, the median level of debt as percent of enterprise value for its peer group is currently 0%.
  • Of the 4 chosen peers for the company, only 2 of the stocks have an outstanding debt balance. Companies with no debt include PIRS-US and ORPN-US.

Access the detailed analysis for CRISPR Therapeutics AG

Key Liquidity Items

Company Debt/Enterprise Value (%) Current Ratio Interest Coverage (x) Cash Flow To Total Debt (%)
Plandai Biotechnology, Inc. 88.75 0.01 -1.48 -9.49
Pieris Pharmaceuticals, Inc. 0 2.87 No interest exp 999
PDL BioPharma, Inc. 129.9 1.94 10.95 22.51
Bioblast Pharma Ltd. 0 6.96 No interest exp 999
CRISPR Therapeutics AG 0 17.79 -81970 999
Peer Median 0 2.87 10.95 999
Best In Class 88.75 17.79 No interest exp 999

Looking for more metrics and analysis for CRISPR Therapeutics AG?

Company Profile

CRISPR Therapeutics AG develops gene-based medicines for patients with serious diseases. Its therapeutic molecular level using the breakthrough genome-editing technology called CRISPR-Cas9. The company was founded by Rodger Novak, Emmanuelle Charpentier and Shaun Patrick Foy in 2014 and is headquartered in Basel, Switzerland.


The information presented in this report has been obtained from sources deemed to be reliable, but AnalytixInsight does not make any representation about the accuracy, completeness, or timeliness of this information. This report was produced by AnalytixInsight for informational purposes only and nothing contained herein should be construed as an offer to buy or sell or as a solicitation of an offer to buy or sell any security or derivative instrument. This report is current only as of the date that it was published and the opinions, estimates, ratings and other information may change without notice or publication. Past performance is no guarantee of future results. Prior to making an investment or other financial decision, please consult with your financial, legal and tax advisors. AnalytixInsight shall not be liable for any party’s use of this report. AnalytixInsight is not a broker-dealer and does not buy, sell, maintain a position, or make a market in any security referred to herein. One of the principal tenets for us at AnalytixInsight is that the best person to handle your finances is you. By your use of our services or by reading any our reports, you’re agreeing that you bear responsibility for your own investment research and investment decisions. You also agree that AnalytixInsight, its directors, its employees, and its agents will not be liable for any investment decision made or action taken by you and others based on news, information, opinion, or any other material generated by us and/or published through our services. For a complete copy of our disclaimer, please visit our website